Scientific summary
Background With > 40,000 new diagnoses in the UK each year and an annual NHS expenditure of > £1B, to which diagnostic investigations are the single largest contributor, colorectal cancer (CRC) is a health priority area. The presenting features known to be associated with CRC are typically vague, and diagnostic yields for investigations are often low. It is current clinical practice to examine the whole large bowel when CRC is suspected in symptomatic patients because of the perceived risk of missing a cancer in the proximal colon when only the distal colorectum is examined by flexible sigmoidoscopy (FS). This is despite evidence of low predictive values of certain CRC symptoms for proximal cancer and the risks/disadvantages of whole-colon investigations (WCIs). In a single-centre study in Portsmouth, England, of 16,433 patients with suspected CRC, > 95% of cancers were detected by FS in patients found not to have iron deficiency anaemia (IDA) or an abdominal mass. This study, and others, suggested that an examination of the distal colorectum by FS is adequate for the majority of patients with distal features of this disease. Further assessment is required of CRC diagnostic yields in the proximal and distal colorectum by presenting features in the wider secondary care population, along with assessment of the diagnostic accuracy of FS for CRC in patients presenting with distal features. This information could be used to inform national guidelines and clinical practice to optimise diagnostic investigations for suspected CRC.
Objectives
The primary research objective is to: l investigate the link between symptoms at presentation and proximal colon cancer risk, and provide evidence of whether or not FS is a clinically effective alternative to WCI in patients whose symptoms do not suggest proximal disease.
The secondary research objectives are to: l determine the diagnostic miss rate of FS for cancers in the colon and rectum l determine the prevalence of proximal and distal CRC in patients referred to hospital with symptoms suggestive of CRC. (54)]. These trials investigated the clinical effectiveness and cost-effectiveness of computerised tomography colonography compared with colonoscopy or barium enema in the diagnosis of CRC and significant polyps (≥ 10 mm). During the SIGGAR trials, all symptoms/clinical signs at referral were recorded at eligibility assessment. Potentially eligible patients were those experiencing symptoms suggestive of CRC, aged ≥ 55 years, clinically judged to need a WCI, judged as fit to undergo full bowel preparation and able to give informed consent. Patients were identified from outpatient clinics and endoscopy and radiology procedural lists, and included suspected cancer 2-week-wait, urgent and routine referrals. Consenting eligible patients were randomised during the SIGGAR trials. To enhance the generalisability of the SOCCER study findings to the broader secondary care population, patients who had been assessed as potentially eligible for SIGGAR were included in the SOCCER study, whether or not they had been randomised.
Methods
Baseline symptoms, referral pathways and planned investigations for all patients were recorded during the SIGGAR eligibility assessment on bespoke pro formas, and this information was transferred to a SOCCER study database for analysis. Additional information to supplement that collected at baseline during the SIGGAR trials that pertained to symptoms and CRC diagnoses was collected from SIGGAR trial reports and hospital endoscopy, radiology, surgery and pathology records.
For patients for whom blood test data were available, anaemia/IDA was defined as laboratory-confirmed anaemia/IDA within 6 months before and 3 months after the date of referral. For patients with a diagnosis of CRC, blood tests dated on or after the date of diagnosis were excluded. Blood test parameters [haemoglobin (Hb) level (g/dl), mean corpuscular volume (MCV; fl) and serum ferritin (µg/l)] were collected from hospital haematology databases. When multiple results were available for a patient, the lowest recorded values were selected. We considered four different definitions of anaemia: broad anaemia, strict anaemia, broad IDA and strict IDA. Broad anaemia was defined solely by Hb level: < 13 g/dl in males and < 12 g/dl in females. Strict anaemia was defined as a Hb level of < 11 g/dl in males and < 10 g/dl in females, or as a Hb level of ≥ 11 g/dl but < 13 g/dl in males or ≥ 10 g/dl but < 12 g/dl in females accompanied by microcytosis (MCV < 80 fl) or low ferritin (< 20 µg/l). Broad IDA was defined as a Hb level of < 13 g/dl in males and < 12 g/dl in females accompanied by microcytosis (MCV < 80 fl) or low ferritin (< 20 µg/l). Strict IDA was defined as a Hb level of < 13 g/dl in males and < 12 g/dl in females accompanied by low ferritin (< 20 µg/l). For patients without blood test data, anaemia was defined by its inclusion on the SIGGAR trial pro forma.
The diagnostic accuracy of symptoms/clinical signs at presentation for site of cancer (proximal vs. distal) was estimated from CRC diagnoses up to 3 years post referral. Cancer diagnoses were obtained from registries via the Health and Social Care Information Centre (HSCIC) and hospital records. Cancers were classified as 'distal' if they were located in the anus, rectum, sigmoid colon or descending colon. Cancers located at colonic sites proximal to the descending colon were classed as 'proximal'. The sensitivities, diagnostic yields and numbers that needed to be examined to diagnose one cancer by presenting features were calculated for proximal and distal cancers. FS miss rates by clinical features for CRC were calculated in patients examined by FS at referral. The results were presented as percentages with 95% binomial exact confidence intervals.
Results
During the SIGGAR trials, 8484 patients with symptoms suggestive of CRC were registered as potentially eligible. For the purposes of the SOCCER study, 1104 patients were excluded prior to analysis: 936 who dissented to the use of their data in future research, 75 who were judged by a clinician as unable to provide informed consent for the use of their data in future research, 27 for whom no symptoms/clinical signs were recorded at presentation, 10 who had duplicate study records and 56 patients who could not be traced through the HSCIC. The final SOCCER cohort analysed comprised 7380 patients (4353 women; 59%). The median age of the cohort was 69 years (interquartile range 62-76 years). The majority of patients were referred via colorectal surgical outpatient clinics (84.5%) and under the suspected cancer 2-week wait pathway (53.9%). We obtained laboratory-confirmed anaemia status for 4741 (64.2%) patients. There were some differences between the patient cohorts with and without blood test data.
The patients with blood test data were slightly older (p < 0.001), less likely to be referred via a colorectal outpatient clinic (p < 0.001) and more likely to be 2-week wait referrals (p < 0.001). Patients with blood test data were also more likely to present with weight loss (p < 0.001) and less likely to present with rectal bleeding (p < 0.001). In the cohort overall, 551 patients were diagnosed with CRC. Overall, the majority of these patients (n = 429, 77.9%) had distal cancer. Distal cancer was less common in the cohort with blood test data (5.1% vs. 7.2% in the cohort without blood test data; p < 0.001), whereas proximal cancer was iv more common in the cohort with blood test data (2.0% vs. 1.2% in the cohort without blood test data; p = 0.007).
Clinical features at referral
In the cohort overall (n = 7380), a change in bowel habit (CIBH) and rectal bleeding were the most frequently presenting symptoms. Over 72% (n = 5382) of patients presented with a symptom profile including a CIBH and more than one-third of patients (37.6%) presented with rectal bleeding.
Rectal bleeding and rectal mass were more common in patients without blood test data (42.2% and 3.2%, respectively) than in those with blood test data (35.0% and 1.7%, respectively; both p < 0.001).
Among 4741 patients with blood test data, the proportions with laboratory-confirmed anaemia depended on the definition of anaemia. Using the broadest definition, 35.0% (n = 1659) of patients were anaemic, whereas 12.0% (n = 567) of patients presented with broad-definition IDA and 6.7% (n = 318) presented with strict-definition IDA. Some clinical features, such as abdominal pain, abdominal mass and a CIBH (except to harder stools and/or less frequent defecation), were more common in women (p ≤ 0.03), whereas more men than women presented with rectal bleeding (p < 0.001) or anaemia (p < 0.001).
The prevalence of rectal bleeding was lower in older than in younger men (27.8% vs. 44.5%) and higher in men than in women (22.8% vs. 37.8%). By contrast, anaemia was substantially more common in older than in younger men (73.3% vs. 23.8%) and more common in men than women (57.2% vs. 18.6%) for the broad definition of anaemia. Similar trends for anaemia by age were observed irrespective of the anaemia definition.
Sensitivity of clinical features for distal and proximal cancers
The sensitivity of any symptom for distal cancer was highest for a CIBH (72%), either in combination with other symptoms or as an isolated symptom. A CIBH was more sensitive for distal than for proximal cancer (71.7% vs. 54.2%; p = 0.002). The sensitivity of rectal bleeding for distal cancer was 64.2%, which was approximately three times higher than for proximal cancer (20.8%; p < 0.001). Anaemia was the most sensitive feature for proximal cancer and was more sensitive for proximal than for distal cancer (p < 0.001).
More than 80% of patients with proximal cancer presented with a symptom profile including anaemia (by the broadest definition).
We examined the most common features (a CIBH, rectal bleeding and anaemia) in further detail in the full cohort of 7380 patients. Overall, 91% of 321 patients diagnosed with cancer who presented without anaemia or an abdominal mass had distal cancer. Of the patients without anaemia or an abdominal mass, 94% (221/234) of those diagnosed with cancer who presented with rectal bleeding had distal tumours. Of patients without anaemia, abdominal mass or rectal bleeding, who presented with a CIBH to looser and/or more frequent stools and were diagnosed with cancer, 100% (15/15) had distal cancer.
Diagnostic yields of clinical features for distal and proximal cancers
Anaemia and abdominal mass were highly predictive of both proximal and distal cancers. In the full cohort of 7380 patients, 2021 patients had either anaemia or an abdominal mass. These clinical features resulted in diagnostic yields of 4.8% for proximal cancer and 6.7% for distal cancer. No other feature exhibited proximal cancer diagnostic yields of more than approximately 1% and the number of patients that needed to be examined to diagnose one proximal cancer in patients without anaemia or an abdominal mass ranged from 75 to 293. Distal cancer diagnostic yields were generally higher than proximal cancer diagnostic yields, which was reflected in the lower numbers needed to be examined to diagnose one distal cancer (range 6-121). More than 1 in 14 patients with rectal bleeding alone (yield 7.5%) or rectal bleeding with a CIBH (yield 11.6%) were diagnosed with distal cancer. The findings were similar in the cohort who had blood test data available. v
Flexible sigmoidoscopy examinations and cancer miss rates
Out of the 7380 patients, 20% (n = 1483) received a FS examination at referral. Patients examined by FS were more likely to present with rectal bleeding (41.3% vs. 36.6%; p = 0.001), abdominal pain (32.1% vs. 28.0%; p = 0.002) or rectal mass (3.2% vs. 2.0%; p = 0.007). Anaemia was more likely to be reported in the cohort without a FS examination (p < 0.001). Proportionately more cancers were diagnosed in patients examined by FS than in patients not examined by FS (9.6% vs. 6.9%; p < 0.001). Proportionately more patients examined by FS than not examined by FS were diagnosed with distal cancer (7.6% vs. 5.4%; p = 0.0014), but the rates of proximal cancer were not significantly different between these subgroups (p = 0.22). Over 78% (n = 112) of the 142 patients examined by FS and subsequently diagnosed with cancer had distal tumours; 101 (90.2%) of these patients had cancer identified at FS and only 11 patients were subsequently diagnosed with distal cancer when cancer had not been identified at FS. Of these 11 patients, only three had 'complete and normal FS'; the remainder had other findings at FS (n = 2) or incomplete FS (n = 6). In the FS group, 31 patients were subsequently diagnosed with proximal cancer and, of these, 22 (71.0%) were patients who had a 'complete and normal' FS.
In 493 patients who presented with rectal bleeding without anaemia or an abdominal mass, 94.5% (n = 69) of the 73 distal cancers were identified at FS. Of the three patients in this subset diagnosed with proximal cancer, two had findings at FS that might have warranted a WCI (in one patient cancer was identified at FS and in one patient three or more lesions were detected). A total of 578 patients presented with a CIBH without anaemia, an abdominal mass or rectal bleeding, 18 of whom were diagnosed with cancer. Only three patients examined by FS who presented with a CIBH were diagnosed with proximal cancer, none of whom had a CIBH to looser and/or more frequent stools. In patients presenting with anaemia or an abdominal mass (n = 359), 78% (n = 18) of distal cancers were identified at FS. Only one patient was subsequently diagnosed with distal cancer after a 'complete and normal' FS. However, 25 (52%) out of 48 patients with cancer in this group had a proximal tumour and 19 (76.0%) of these patients had a 'complete and normal' FS.
Conclusions
The diagnostic yield of proximal colon cancer was highest in patients presenting with anaemia or an abdominal mass. The rates of distal CRC were also comparatively high in these patients. By contrast, certain features that were present in a large proportion of patients were associated with relatively low risk of proximal cancer compared with anaemia/abdominal mass. Proximal cancer diagnoses were rare in patients presenting with rectal bleeding or a CIBH to looser and/or more frequent stools, a subgroup that constituted 40% of the total cohort. Our findings now add to the body of evidence supporting recommendations, which have yet to become standard practice, for tailoring diagnostic investigations for suspected CRC based on presenting features. As diagnostics is the single largest contributor to the £1.1B NHS cost associated with CRC, a cost-effectiveness analysis of symptom-based tailoring of diagnostic investigations for suspected CRC is recommended.
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